# US 2025/0084154 A1 · Inhibition of eosinophilic traps

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084154 A1
- Document ID: US20250084154A1
- Status: Published application
- Kind: A1
- Application number: 18/289,559
- Filed: 2022-05-04
- Published: 2025-03-13
- Earliest claimed: 2021-05-04
- Assignees: Citryll B.V.
- Applicants: Citryll B.V.
- Inventors: Helmuth Hendrikus Gerardus VAN ES; Renato Gerardus Silvano CHIRIVI; Daphne MONTIZAAN; Eric Charles MELDRUM
- Web page: https://patentgrep.com/patent/US20250084154A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides methods for the inhibition of Eosinophil Extracellular Trap (EET) formation. In particular, the invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes, for use in methods to inhibit or detect EET formation. The methods may be for the diagnosis, treatment or prevention of any disease or condition which includes an EET-associated pathology.

## Claims

### Claim 1

A method of inhibiting the formation of eosinophil extracellular traps (EETs), the method comprising administering an antibody or binding fragment thereof that specifically binds to a citrullinated epitope on deiminated human histone 2A and/or histone 4 to a sample or a subject in which eosinophils are present.

### Claim 2 (depends on 1)

The method according to claim 1, which is for the prevention or treatment of a disease or condition in a subject, and which method comprises administering said antibody or binding fragment thereof to the subject in a prophylactically or therapeutically effective amount.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the disease or condition includes an EET-associated pathology.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the disease or condition is an eosinophilic disease or condition.

### Claim 5 (depends on 4)

The method according to claim 4, wherein said eosinophilic disease or condition is an eosinophilic disease or condition of the skin; a respiratory eosinophilic disease or condition; a gastro-intestinal eosinophilic disease or condition; an allergic disease or condition; or a helminth, fungal, viral, or bacterial infection.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the disease or condition is selected from: Bullous Pemphigoid, Atopic dermatitis, allergic contact dermatitis, Eosinophilic Asthma, Chronic RhinoSinusitis with Nasal Polyposis (CRSwNP), Allergic sinusitis, Allergic bronchopulmonary aspergillosis, Eosinophilic chronic rhinosinusitis, Eosinophilic Esophagitis (EoE), HyperEosinophilic Syndrome (HES), Eosinophilic Granulomatosis with PolyAngitis (EGPA), Eosinophilic otitis media (EOM), and Drug Reaction with Eosinophilic & Systemic Symptoms (DRESS), arteriosclerosis, and vasculitis.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the disease or condition is selected from: Eosinophilic Asthma, Chronic RhinoSinusitis with Nasal Polyposis (CRSwNP), Eosinophilic chronic rhinosinusitis, Eosinophilic otitis media (EOM), arteriosclerosis and vasculitis.

### Claim 8 (depends on 1)

The method according to claim 1, which is for the ex vivo inhibition or detection of EET formation in a sample, and which comprises administering said antibody or binding fragment thereof to the sample and incubating under conditions suitable for binding to occur, optionally wherein the sample is of a body fluid obtained from a subject, such as serum or blood, and optionally wherein the sample is processed for example to isolate eosinophils.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the antibody or binding fragment thereof comprises:
a) CDR1 of VL, wherein the CDR comprises or consists of the amino acid sequence QSL-X1-D-X2-D-X3-KTY, wherein X1 is V or L, X2 is T, S, A or N and X3 is G or A, preferably wherein the amino acid sequence is not QSLLDSDGKTY (SEQ ID NO: 36) or QSLVDSDGKTY (SEQ ID NO: 37); and
b) at least one CDR selected from SEQ ID NOs: 1 to 5, optionally at least the CDRs of SEQ ID NO: 3 and SEQ ID NO: 5, and preferably all five CDRs of SEQ ID NOs: 1 to 5.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the antibody or binding fragment thereof comprises:
a) a VL CDR1 of SEQ ID NOs: 6, 7, 8, 9 or 10; and
b) the CDRs of SEQ ID NOs: 1 to 5;
OR
a) the VL CDRs from any one of SEQ ID NOs: 13, 14, 15, 16 or 17; and
b) the heavy chain variable domain amino acid sequence of SEQ ID NO: 11 or 12.

### Claim 11 (depends on 9)

The method according to claim 9, wherein the antibody or binding fragment thereof comprises:
(I) a light chain variable region comprising:
a) a VL CDR1, wherein the CDR comprises or consists of the amino acid sequence QSL-X1-D-X2-D-X3-KTY, wherein X1 is V or L, X2 is T, S, A or N and X3 is G or A, preferably wherein the amino acid sequence is not QSLLDSDGKTY (SEQ ID NO: 36) or QSLVDSDGKTY (SEQ ID NO: 37), and optionally wherein said CDR1 is selected from SEQ ID NO: 6, 7, 8, 9 or 10; and
b) at least one, and preferably both, of the VL CDR2 of SEQ ID NO: 4 and the VL CDR3 of SEQ ID NO: 5; and
(II) a heavy chain variable region comprising:
c) the amino acid sequence of SEQ ID NO: 11 or 12; or
d) a fragment of at least 7 amino acids of (c), wherein the antibody or binding fragment thereof retains the ability of being specifically reactive with a citrullinated epitope on deiminated human histone 2A and/or histone 4; or
e) a variant of (c) having at least 70% amino acid sequence identity to a sequence of (c), wherein the antibody or binding fragment thereof retains the ability of being specifically reactive with a citrullinated epitope on deiminated human histone 2A and/or histone 4.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the antibody or binding fragment thereof comprises:
a) the heavy chain variable domain amino acid sequence of SEQ ID NO: 11 and the light chain variable domain amino acid sequence of SEQ ID NO: 13;
b) the heavy chain variable domain amino acid sequence of SEQ ID NO: 11 and the light chain variable domain amino acid sequence of SEQ ID NO: 14;
c) the heavy chain variable domain amino acid sequence of SEQ ID NO: 11 and the light chain variable domain amino acid sequence of SEQ ID NO: 15;
d) the heavy chain variable domain amino acid sequence of SEQ ID NO: 11 and the light chain variable domain amino acid sequence of SEQ ID NO: 16;
e) the heavy chain variable domain amino acid sequence of SEQ ID NO: 11 and the light chain variable domain amino acid sequence of SEQ ID NO: 17;
f) the heavy chain variable domain amino acid sequence of SEQ ID NO: 12 and the light chain variable domain amino acid sequence of SEQ ID NO: 13;
g) the heavy chain variable domain amino acid sequence of SEQ ID NO: 12 and the light chain variable domain amino acid sequence of SEQ ID NO: 14;
h) the heavy chain variable domain amino acid sequence of SEQ ID NO: 12 and the light chain variable domain amino acid sequence of SEQ ID NO: 15;
i) the heavy chain variable domain amino acid sequence of SEQ ID NO: 12 and the light chain variable domain amino acid sequence of SEQ ID NO: 16; or
j) the heavy chain variable domain amino acid sequence of SEQ ID NO: 12 and the light chain variable domain amino acid sequence of SEQ ID NO: 17.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the antibody or binding fragment thereof specifically binds to a peptide selected from the group consisting of SEQ ID NOs: 18, 19, 20, 21 and 22, and binds deiminated human histone 2A and/or histone 4, preferably with an affinity of at least 1 nM or less.

### Claim 14 (depends on 1)

The method according to claim 1, wherein (i) the antibody or binding fragment thereof is selected from the group consisting of recombinant antibodies, single chain antibodies, single chain variable fragments (scFv), variable fragments (Fv), fragment antigen-binding regions (Fab), single-domain antibodies (sdAb), VHH antibodies, nanobodies, camelids-derived single-domain antibodies, shark IgNAR-derived single-domain antibody fragments (VNAR), diabodies, triabodies, Anticalins and aptamers, and is preferably a full-length antibody, and/or (ii) wherein the antibody or binding fragment thereof is conjugated to an additional moiety.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the antibody or binding fragment thereof comprises an Fc region, such as an IgG1, IgG2, IgG3 or IgG4 region, optionally wherein the heavy chain constant region comprises SEQ ID NO: 23 or 56, and/or the light chain constant region comprises SEQ ID NO: 24.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the antibody comprises the heavy chain variable domain amino acid sequence of SEQ ID NO: 11, the light chain variable domain amino acid sequence of SEQ ID NO: 16, the heavy chain constant region amino acid sequence of SEQ ID NO: 23 or 56, and the light chain constant region amino acid sequence of SEQ ID NO: 24.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the method inhibits the formation of eosinophil extracellular traps (EETs) and neutrophil extracellular traps (NETs) at the same time.

### Claim 18

A method of treating or preventing a lung disorder comprising administering an antibody or binding fragment thereof that specifically binds to a citrullinated epitope on deiminated human histone 2A and/or histone 4 to a subject with said lung disorder.

### Claim 19 (depends on 18)

The method of claim 18, wherein:
(a) the condition is an inflammatory lung disorder;
(b) the lung disorder is characterised by an increase in the level of neutrophils and/or eosinophils in the lungs of the subject;
(c) the method further comprises administering a corticosteroid; and/or
(d) the subject has a lung disorder which is not responsive to corticosteroids.
